LONDON, April 24 (Reuters) - Some batches of Sanofi-Aventis's blood thinning heparin injection Clexane [a.k.a. Lovenox] on the UK market contain low levels of the impurity over-sulphated chondroitin sulphate, the country's drug watchdog said on Thursday.
The Medicines and Healthcare products Regulatory Agency said there was currently no evidence this was associated with any risk to patients. Doctors could continue to use the product but should remain vigilant to any adverse reactions. <<
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”